RegenInnopharm

PU001
PU001 is a potential candidate drug to treat diabetic foot ulcer with local administration, a type of incurable wound commonly occurring on the feet of patients with diabetes.

Development stage : First-in-human trial is anticipated to initiate in Q1 of 2024

When an ulcer occurs with concurrent peripheral arterial disease (PAD) in patients with diabetes, it usually does not respond to the standard of therapy, lowers quality of life over a long period, and, in rare cases, may even become life-threatening.
While this disease causes a financial burden as high as 44 million US dollars per year in Korea, no drugs are known to modify the condition or recognized as a standard therapy.
PU001, being developed by RegenInnopharm Inc., is expected to induce complete wound healing through multimodal tissue regeneration.

PN001
PN001 is a potential candidate drug to treat stroke by reducing brain damage and inducing regeneration of the affected tissue, which would minimize its sequelae.

Development stage : anticipated to submit IND by the second half of 2024

An ischemic stroke occurs when a blood vessel that supplies the brain becomes blocked. Depending on the damage in the affected brain part, it may cause a permanent loss of function.
It is reported that there are over 7.6 million new ischemic strokes each year, and the lifetime cost per ischemic stroke survivor is $90,981. Revascularization is mainly emphasized as a standard of care, and no medication is available with proven effects of regeneration of damaged brain and/or functional recovery.
PN001, being developed by RegenInnopharm Inc., is expected to reduce brain damage from stroke and restore brain function with only 1 to 2 doses.

RH001
RH001 is a potential candidate drug to treat acute myocardial infarction. Its treatment during the acute phase is expected to contribute to the recovery of heart function close to normal condition by reducing infarct volume and regenerating injured heart tissue.

Development stage : anticipated to submit IND by the second half of 2025

Acute myocardial infarction is caused by a blockage in the arteries that supply blood and oxygen to the heart, resulting in damage to the heart muscle. It remains the leading cause of cardiovascular death.
Globally, its incidence rate keeps growing by about 5% annually. In addition to its substantial mortality and morbidity burden, it carries an enormous economic burden from medical costs and loss of labor. However, no therapeutic option can help repair the damaged tissue and heart function other than standard revascularization.
RH001, being developed by RegenInnopharm Inc., is expected to reduce mortality and morbidity by regenerating the damaged heart tissue and restoring normal heart function with only 1 to 2 doses.